IP Group (LSE:IPO) - Hisse Senedi Fiyatı, Haberler ve Analizler

IPO Stoklara Genel Bakış

IPO temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Gelirin yılda 106.56% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( £-213M )

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

IP Group Plc Rakipler

Molten Ventures

LSE:GROW

UK£594.5m

Arix Bioscience

LSE:ARIX

UK£176.5m

Octopus Renewables Infrastructure Trust

LSE:ORIT

UK£399.8m

Symphony International Holdings

LSE:SIHL

US$156.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti IP Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	UK£0.43
52 Haftanın En Yüksek Seviyesi	UK£0.61
52 Haftanın En Düşük Seviyesi	UK£0.36
Beta	1.39
11 Aylık Değişim	-7.71%
3 Aylık Değişim	2.25%
1 Yıllık Değişim	-18.06%
33 Yıllık Değişim	-62.65%
5 Yıllık Değişim	-28.05%
Halka arzdan bu yana değişim	-34.70%

Son Haberler & Güncellemeler

Recent updates

What Type Of Shareholders Make Up IP Group Plc's (LON:IPO) Share Registry?

Dec 10

Hissedar Getirileri

	IPO	GB Capital Markets	GB Pazar
7D	3.9%	3.4%	2.2%
1Y	-18.1%	28.2%	8.8%

Getiri vs. Endüstri: IPO geçen yıl % 26.5 oranında getiri sağlayan UK Capital Markets sektörünün gerisinde kaldı.

Getiri vs Piyasa: IPO geçen yıl % 8.3 oranında getiri sağlayan UK Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is IPO's price volatile compared to industry and market?
IPO volatility
IPO Average Weekly Movement	5.3%
Capital Markets Industry Average Movement	3.5%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.2%
10% least volatile stocks in GB Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: IPO son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: IPO 'nin haftalık oynaklığı ( 5% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2001	95	Greg Smith	www.ipgroupplc.com

IP Group Plc, büyüme sermayesi şirketlerinde tohum / başlangıç, erken girişim, gelişmekte olan büyüme, olgun, orta girişim, geç girişim, kuluçka, mezzanine konularında uzmanlaşmış bir özel sermaye ve girişim sermayesi şirketidir. Enerji, malzeme, sağlık, bilgi teknolojileri, iletişim hizmetleri, kamu hizmetleri, yaşam bilimleri, deeptech, cleantech, kimya, bilim ve inovasyon şirketlerine yatırım yapmayı tercih etmektedir. Firma Avrupa'da yatırım yapmayı tercih etmektedir.

IP Group Plc Temel Bilgiler Özeti

IP Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
IPO temel i̇stati̇sti̇kler
Piyasa değeri	UK£426.49m
Kazançlar(TTM)	-UK£226.30m
Gelir(TTM)	n/a

-2.0x

P/S Oranı

-1.9x

F/K Oranı

IPO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
IPO gelir tablosu (TTM)
Gelir	-UK£212.50m
Gelir Maliyeti	UK£0
Brüt Kâr	-UK£212.50m
Diğer Giderler	UK£13.80m
Kazançlar	-UK£226.30m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.23
Brüt Marj	100.00%
Net Kâr Marjı	106.49%
Borç/Özkaynak Oranı	14.2%

IPO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

IPO Stoklara Genel Bakış

Ödüller

Risk Analizi

IP Group Plc Rakipler

LSE:GROW

UK£594.5m

LSE:ARIX

UK£176.5m

LSE:ORIT

UK£399.8m

LSE:SIHL

US$156.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd from Epidarex Capital, IP Group Plc (LSE:IPO) and Scottish Investment Bank Limited.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

First half 2024 earnings released: UK£0.11 loss per share (vs UK£0.053 loss in 1H 2023)

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 99%

Recent updates

Dr. Falk Pharma GmbH acquired Kynos Therapeutics Ltd from Epidarex Capital, IP Group Plc (LSE:IPO) and Scottish Investment Bank Limited.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

Visa Inc. (NYSE:V) signed a definitive agreement to acquire Featurespace from from Chrysalis Investments Limited (LSE:CHRY), Highland Europe (UK) LLP, IP Group Plc (LSE:IPO), Insight Venture Management, LLC, MissionOG Capital, LLC, and TTV Capital LLC.

First half 2024 earnings released: UK£0.11 loss per share (vs UK£0.053 loss in 1H 2023)

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 99%

IP Group Plc to Report First Half, 2024 Results on Sep 17, 2024

Forcepoint LLC entered into a definitive agreement to acquire Garrison Technology Limited from IP Group Plc (LSE:IPO).

Price target decreased by 15% to UK£1.13

CEO & Executive Director recently sold UK£98k worth of stock

Full year 2023 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

IP Group Plc, Annual General Meeting, Jun 12, 2024

New minor risk - Financial data availability

IP Group Plc to Report Fiscal Year 2023 Results on Mar 13, 2024

IP Group Plc (LSE:IPO) commences an Equity Buyback Plan for 103,677,065 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2023.

Price target increased by 7.5% to UK£1.32

First half 2023 earnings released: UK£0.052 loss per share (vs UK£0.30 loss in 1H 2022)

Now 21% undervalued

IP Group Plc to Report First Half, 2023 Results on Aug 02, 2023

Price target decreased by 8.8% to UK£1.18

Full year 2022 earnings released: UK£0.33 loss per share (vs UK£0.42 profit in FY 2021)

Now 24% undervalued

IP Group Plc to Report Fiscal Year 2022 Results on Mar 08, 2023

Scaleworks Inc. acquired Import.io Ltd.

IP Group plc Appoints Anita Kidgellas an Independent Non-Executive Director

Now 21% undervalued

Insufficient new directors

Insufficient new directors

Ip Group plc Announces the Initiation of Its Phase 2B Trial of Mbs2320, Its Lead Drug in Rheumatoid Arthritis, with the First Patients Now Dosed

Price target decreased to UK£1.32

First half 2022 earnings released

IP Group Plc Declares an Interim Dividend in Respect of the Period from 1 January 2022 to 30 June 2022, Payable on or Around 19 September 2022

IP Group Plc to Report First Half, 2022 Results on Aug 03, 2022

IP Group Plc Launches 'Kiko Ventures' Platform to Deepen Its Support for Transformative Climate Technology

Price target decreased to UK£1.47

Price target decreased to UK£1.47

Full year 2021 earnings: EPS and revenues exceed analyst expectations

IP Group Plc to Report Fiscal Year 2021 Results on Mar 16, 2022

Insider recently bought UK£61k worth of stock

Investor sentiment improved over the past week

First half 2021 earnings released: EPS UK£0.11 (vs UK£0.011 in 1H 2020)

NeoGenomics Laboratories, Inc. completed the acquisition of remaining 88.95% stake in Inivata Limited from a group of sellers.

IP Group Plc Announces Inaugural Dividend, Payable on 16 June 2021

Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.071 loss in FY 2019)

Athenex, Inc. (NasdaqGS:ATNX) acquired Kuur Therapeutics Limited.

Full year 2020 earnings released: EPS UK£0.17 (vs UK£0.071 loss in FY 2019)

Revenue and earnings beat expectations

IP Group Plc, Annual General Meeting, Jun 09, 2021

Price target raised to UK£1.43

IP Group Plc to Report Fiscal Year 2020 Results on Mar 10, 2021

New 90-day high: UK£1.18

Centessa Pharmaceuticals Limited acquired ApcinteX from Medicxi Ventures (UK) LLP, Touchstone Innovations Plc, Cambridge Enterprise Seed Funds and IP Group Plc (LSE:IPO).

Price target raised to UK£1.24

New 90-day high: UK£0.99

What Type Of Shareholders Make Up IP Group Plc's (LON:IPO) Share Registry?

New 90-day high: UK£0.94

New 90-day high: UK£0.85

New 90-day high: UK£0.85